Levadopa Related Compound A Inhibitor

Levadopa Related Compound A is the 6-hydroxy derivative of the amino acid L-DOPA with neurotoxic properties. Exogenously administered 6-Hydroxy-L-DOPA is biotransformed by an amino acid decarboxylase to the highly potent and catecholamine-selective neurotoxin, 6-Hydroxydopamine.

Luurtsema G, Boersma HH, Schepers M, de Vries AMT, Maas B, Zijlma R, de Vries EFJ, Elsinga PH. Improved GMP-compliant multi-dose production and quality control of 6-[(18)F]fluoro-L-DOPA. EJNMMI Radiopharm Chem. 2017;1(1):7. doi: 10.1186/s41181-016-0009-1. Epub 2016 Apr 4. PubMed PMID: 29564384; PubMed Central PMCID: PMC5843807.
Pinna A, Pontis S, Borsini F, Morelli M. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse. 2007 Aug;61(8):606-14. PubMed PMID: 17476684.
Yamato H, Kannari K, Shen H, Suda T, Matsunaga M. Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport. 2001 May 8;12(6):1123-6. PubMed PMID: 11338177.
Kostrzewa RM, Kostrzewa JP, Brus R. Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum. Amino Acids. 2000;19(1):183-99. PubMed PMID: 11026489.

Small volumes of Levadopa Related Compound A, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756422 is an inhibitor targeting Levadopa Related Compound A.